This review summarizes recent studies on the predictive value of molecular markers in adult gliomas, including 1p/19q codeletion, MGMT methylation, IDH mutation and markers identified using omics and next-generation sequencing studies.
INTRODUCTION
Until recently, treatment decisions in glioma were based on clinical, radiological and histological factors with little use of predictive molecular markers [1] . When treating anaplastic gliomas, many neurooncologists used the 1p/19q codeletion status for care decisions but this strategy was not supported by strong evidence [2 & ]. In glioblastoma patients less than 70 years, MGMT methylation predicts a stronger benefit of temozolomide radiochemotherapy, but is not decisional in this population, as unmethylated patients can benefit from this regimen [3] . Now, the long-term results of the Radiation Therapy Oncology Group (RTOG) and European Organization for Research and Treatment of Cancer (EORTC) trials have clearly established that the 1p/19q codeletion predicts a benefit for early chemotherapy in anaplastic gliomas, and two phase III trials suggest that MGMT methylation should guide treatment decisions in elderly patients with glioblastoma [4 && -7 && ]. In addition, omics and next-generation sequencing studies have identified gene expression signatures and molecular markers that could predict treatment efficacy, particularly when using targeted therapies [8 && -10 && ].
CHROMOSOME 1P/19Q CODELETION
In 1998, the 1p/19q codeletion has been associated with response to chemotherapy in anaplastic oligodendrogliomas [11] . However, in contrast to its well established prognostic value, the predictive value of the 1p/19q codeletion had, until recently, remained a topic of debate. Chromosome 1p/19q codeletion is strongly associated with classical oligodendroglial features. It results from an unbalanced translocation between the entire arm of 19p and 1q [12] . At the genomic level, it corresponds to a complete loss of the 1p and 19q arms, which is important to distinguish from 1p partial distal deletions (typically 1p36) that occur in astrocytic tumors and are associated with a poor prognosis [13] [14] [15] . Using fluorescence in-situ hybridization or loss of heterozygosity techniques with probes focusing solely on 1p36 loci (as classically performed) may be insufficient to discriminate between the two types of 1p deletions [13] . 1p/19q codeletion is almost always associated with an IDH1/ IDH2 mutation and is exclusive from TP53, ATRX mutations and from EGFR and other gene amplifications [ . These mutations are also present in the majority of primary glioblastomas. In contrast, they are rare in IDH mutated non1p/19q-codeleted gliomas. These tumors harbor ATRX mutations that maintain telomere length independently of telomerase activity (alternative lengthening of telomeres) [24 && ]. At the gene expression level 1p/19q codeletion is associated with a proneural gene expression profile and the expression of neuronal genes [25] . In particular, internexine alpha expression can be used as a surrogate marker of the 1p/19q codeletion and has a strong prognostic value in anaplastic gliomas [26] [27] [28] .
In the mid 1990s, two phase III studies -one by the RTOG and the other by the EORTC -were initiated to test if adding PCV (procarbazine CCNU vincristine) chemotherapy to radiotherapy as part of the initial treatment might improve the overall survival (OS) of patients with anaplastic oligodendroglial tumors (AOTs). The first results of these two studies, published in 2006, showed that PCV and radiotherapy increased progression-free survival (PFS) but did not affect OS and that this outcome was true irrespective of 1p/19q status [29, 30] . After a median follow-up of 11 years, the long-term results of both studies now clearly demonstrate that 1p/19q codeletion is not only a major prognostic factor but also a major predictive factor of early chemotherapy benefit [4 && ,5 && ]. In patients with 1p/19q-codeleted tumors, PCV and radiotherapy resulted in a nearly three-fold increase in median PFS compared with radiotherapy alone (8.4 years versus 2.9 years in the RTOG study; 13 years versus 4.1 years in the EORTC study) and in a two-fold increase of the median OS (14.7 years versus 7.3 years in the RTOG study; median OS not reached versus 9.3 years in the EORTC study). In contrast, early PCV was associated with only a modest increase in PFS with no effect on OS in non1p/19q-codeleted tumors. Therefore, the updated results of the RTOG and EORTC study define radiotherapy and PCV as the new standard of care for newly diagnosed 1p/19q-codeleted AOTs. However, the survival curves of patients with 1p/ 19q-codeleted AOTs treated with radiotherapy alone or radiotherapy and PCV only began to diverge at 5 years, which suggests that some 1p/19q-codeleted tumors are not sensitive to PCV. As such, additional biomarkers need to be identified within 1p/19q tumors. Although radiotherapy and PCV did not improve median OS in non1p/19q-codeleted tumors, the survival curves indicated a higher rate of long-term survival in this group compared with those in the group that received radiotherapy alone. Because noncodeleted tumors that harbor IDH mutations are associated with a far better prognosis than non1p/19q-codeleted tumors that express wild-type IDH, assessing the value of IDH status to predict early chemotherapy benefits in non1p/19qcodeleted tumors would be interesting [16] . In the EORTC study, robust conclusions could not be made because of the limited number of patients with AOTs that were both non1p/19q-codeleted and IDHmutated. Further molecular analyses from the RTOG study are expected. Interestingly, a translational study on the EORTC study demonstrated that the benefit of early PCV chemotherapy could be more reliably predicted by tumor gene expression profiles [8 && ]. One hundred and forty AOTs were assigned to main gliomas subtypes [called intrinsic glioma
KEY POINTS
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In the near future, predictive biomarkers will likely guide the use of targeted therapies. subtypes (IGS)] previously identified based on unsupervised gene expression analysis. Tumors assigned to IGS-9 (which was enriched in 1p/19q codeleted tumors) significantly benefited from adjuvant PCV. A similar (although nonsignificant) trend was observed for tumors assigned to IGS-17 (which was enriched in IDH mutated but non1p/19q-codeleted tumors).
In low-grade gliomas (LGGs), 1p/19q codeletion also has a strong prognostic value. The median survival duration is 12-15 years in the presence of the 1p/19q codeletion and 5-8 years in the absence of the codeletion [1] . In the largest published series of patients treated with up-front temozolomide, the 1p/19q codeletion was associated with both a higher response rate (72 versus 46%) to chemotherapy and a longer duration of response (>40 versus 20 months) [31] . However, its predictive value needs to be confirmed in prospective clinical trials [32] . Analysis of the outcome according to the 1p/19q codeletion in the RTOG phase III trial (radiotherapy versus radiotherapy and PCV in unfavorable LGGs) and in the EORTC/NCIC phase III trial (up-front radiotherapy versus up-front temozolomide in progressive LGGs) are expected to clarify the predictive and clinical values of 1p/19q in LGGs.
O6-METHYLGUANINE-DNA METHYL TRANSFERASE
MGMT silencing through methylation of its promoter induces low expression of MGMT protein and decreases DNA-repair activity, which increases sensitivity to alkylating agents.
MGMT methylation occurs in approximately 40% of glioblastomas. In 2005, it was identified as both a strong prognostic and predictive marker in glioblastomas treated with temozolomide radiochemotherapy [33] . However, assessment of MGMT methylation was not incorporated into treatment decisions because MGMT methylation was only demonstrated to be a quantitative predictive marker. Indeed, when the effect of concomitant and adjuvant temozolomide versus radiotherapy alone was evaluated in the EORTC/NCIC 26981/ 22981 glioblastoma trial, the benefit of radiochemotherapy was higher in MGMT-methylated patients (23.4 versus 15.3 months, P ¼ 0.004) than in MGMT-unmethylated patients (12.6 versus 11.8 months, P ¼ 0.035). However, the latter group still benefited from this treatment, particularly in terms of long-term survival [34] .
A retrospective analysis of MGMT methylation was recently performed in two phase III trials, the NOA-8 and the Nordic trials, which evaluated the effect of radiotherapy versus temozolomide chemotherapy in elderly glioblastoma patients [6 && ,7 && ]. MGMT methylation was analyzed in 56 and 69% of patients in the NOA-8 and the Nordic trial, respectively. In the NOA-8 trial (patients >65 years), MGMT-methylated patients had a longer PFS when treated with temozolomide as opposed to radiotherapy (8.4 versus 4.6 months, P ¼ 0.01), whereas MGMT-unmethylated patients had a longer PFS when treated with radiotherapy than with temozolomide (4.6 versus 3.3 months, P ¼ 0.01). A similar yet not significant trend was observed for OS. The Nordic trial (patients >60 years) showed a nonsignificant trend toward longer OS in MGMT-methylated patients when treated with temozolomide rather than with radiotherapy (hazard ratio ¼ 0.64, P ¼ 0.07), but MGMT-unmethylated patients did not fare better when treated with radiotherapy than with temozolomide. PFS data were not available for this trial, as these data were deliberately not collected. These results, together with another retrospective study, suggest that MGMT methylation could guide treatment decision in elderly patients with glioblastoma [35 & ]. However, the data are not yet robust enough to be translated into the clinic and need prospective validation. The results of the NCIC/EORTC phase III trial (accelerated radiotherapy versus accelerated radiotherapy and temozolomide) are awaited to clarify the predictive value of this alteration in elderly patients with glioblastomas and the place of combined radiochemotherapy in this population.
Until now, the use of MGMT methylation as a predictive factor has also been limited by the fact that the optimal technique to study MGMT methylation is still debated. In a recent study, the rate of MGMT-methylated patients varied from 33 to 60% depending on the method that was used [36 && ]. Methylation-specific PCR has been used as a standard to study MGMT methylation, but this method is only qualitative and lacks automation. Therefore, alternative semiquantitative and quantitative techniques have been developed. However, these techniques do not study exactly the same regions of the MGMT promoter. Therefore, as the methylation pattern of the promoter can be heterogeneous, some patients are classified as methylated or as unmethylated depending on the technique used In contrast to glioblastomas, MGMT methylation in anaplastic gliomas appears until now only as a prognostic factor without predictive value [39, 40] . This may be explained by the fact that, in these tumors, MGMT methylation is tightly associated with IDH mutation and a diffuse hypermethylated phenotype [38 && ,41].
IDH1/IDH2 MUTATIONS
Isocitrate dehydrogenase mutations have a strong diagnostic and prognostic value in adult diffuse gliomas but no clear predictive value [42] . Whether IDH mutated non1p/19q-codeleted anaplastic gliomas benefit from early PCV chemotherapy remains to be determined. The IDH mutation has been suggested to predict the response to first-line temozolomide chemotherapy in low-grade gliomas, but this finding requires confirmation [43] . An analysis of the outcome according to the IDH mutation in the RTOG phase III trial (radiotherapy versus radiotherapy and PCV in unfavorable LGGs) and the EORTC/NCIC phase III trial (up-front radiotherapy versus up-front temozolomide in progressive LGGs) is expected to clarify the predictive value of IDH mutation in LGGs. However, IDH mutation might predict the efficacy of mutant IDH inhibitors in the future. Important advances have been achieved in the understanding of the pathophysiology of IDH mutations. As suggested by the distribution of its mutations, the mutated IDH protein has been shown to be oncogenic [44 && ]. IDH mutations result in the abnormal production of 2-hydroxyglutarate (2-HG) that is structurally similar to a-ketoglutarate. 
NEW PREDICTIVE BIOMARKERS IDENTIFIED THROUGH OMICS AND NEXT-GENERATION SEQUENCING STUDIES
Omics studies have enabled the classification of gliomas into molecularly homogeneous subgroups that are of prognostic value, independently of histology [49] . These subgroups could also be of predictive value. Erdem-Eraslan et al. ] demonstrated that the gene expression profiles of anaplastic glioma could be used to predict the benefit of early PCV chemotherapy. In glioblastomas, Verhaak et al. [50] suggested that the molecular classification into four subclasses (classical, mesenchymal, proneural and neural) predicts the benefit of a more intensive treatment. Patients with mesenchymal and classical glioblastomas showed increased OS when treated with temozolomide radiochemotherapy and/or more than three cycles of adjuvant temozolomide, which was not the case for patients with proneural glioblastomas. The classical subclass has also been suggested to be associated with a higher response rate to first-line chemotherapy [51] . However, these results require validation in prospective studies. Extensive molecular studies have also identified recurrent alterations that could predict the efficacy of targeted therapies. BRAF alterations were first identified in the majority of pilocytic astrocytomas suggesting that these tumors might be candidates for BRAF inhibitors [52, 53] . In these tumors, the most frequent alteration is a KIAA1549-BRAF fusion transcript. This alteration is also found in a small subset of diffuse gliomas, in particular 1p/19q-codeleted oligodendrogliomas [54 & ]. Subsequently, activating BRAF V600E mutations were found in two-thirds of pleomorphic xanthoastrocytomas and gangliogliomas as well as in 50% of epithelioid glioblastomas (an uncommon glioblastoma variant not recognized in the WHO 2007 classification) [55,56 & ,57,58,59 & ]. However, this mutation is rare (<5%) in other diffuse gliomas, including glioblastomas. Interestingly, this mutation can be easily assessed using a V600E mutation-specific antibody and a small case study suggested that vemurafenib (a potent BRAF inhibitor with clinically meaningful activity against BRAFmutated metastatic melanoma) could be active in adults with recurrent pleomorphic xanthoastrocytomas that showed a BRAF mutation [60,61 & ]. MET is amplified in approximately 5% of glioblastomas and could predict the efficacy of crizotinib, an oral smallmolecule inhibitor of the MET and anaplastic lymphoma kinase (ALK) tyrosine kinases that is highly effective in lung cancers with ALK translocation [62 & ]. Oncogenic EGFR alterations are much more frequent (40%), but anti-EGFR therapies have failed to demonstrate clinical activity until now. However, new EGFR tyrosine kinase inhibitors could be more effective [63 && ]. Finally, high-throughput RNA sequencing studies identified recurrent activating FGFR fusion transcripts in a small subset of glioblastomas (3%) that might be good candidates for the use of anti-FGFR-targeted therapies [9 && ,10 && ].
CONCLUSION
Major advances have been achieved in the molecular characterization of adult gliomas, which led to the identification of strong diagnostic and prognostic markers. Predictive biomarkers are more difficult to identify and need to be validated in prospective clinical trials before being translated into the clinic. Currently, the 1p/19q codeletion is the only well established predictive marker with clinical utility. However, it is likely that other molecular markers, such as MGMT methylation, IDH mutation and those identified using omics and next-generation sequencing studies, will further guide treatment decisions for gliomas in the near future. Because many of these new predictive biomarkers will most likely be present in only small subsets of patients, facilities that can perform prospective highthroughput molecular analyses of gliomas will be necessary :337-343. The long-term results of the RTOG 9402 trial define radiotherapy and PCV as the new standard of care for newly diagnosed 1p/19q-codeleted anaplastic oligodendroglial gliomas and demonstrate that the 1p/19q codeletion is a strong predictive marker of early PCV chemotherapy benefit in these tumors.
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